spacer
spacer

PDBsum entry 3gs4

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hormone PDB id
3gs4
Jmol
Contents
Protein chain
115 a.a. *
Ligands
7BD ×2
Waters ×181
* Residue conservation analysis
PDB id:
3gs4
Name: Hormone
Title: Human transthyretin (ttr) complexed with 3-(9h-fluoren-9- ylideneaminooxy)propanoic acid (inhibitor 15)
Structure: Transthyretin. Chain: a, b. Fragment: unp residues 21 to 147. Synonym: prealbumin, tbpa, ttr, attr. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: ttr, palb. Expressed in: escherichia coli. Expression_system_taxid: 562
Resolution:
1.78Å     R-factor:   0.228     R-free:   0.278
Authors: N.N.Mohamedmohaideen,S.K.Palaninathan,E.Orlandini, J.C.Sacchettini
Key ref: S.K.Palaninathan et al. (2009). Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. PLoS One, 4, e6290. PubMed id: 19621084
Date:
26-Mar-09     Release date:   28-Jul-09    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P02766  (TTHY_HUMAN) -  Transthyretin
Seq:
Struc:
147 a.a.
115 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     extracellular region   5 terms 
  Biological process     transport   5 terms 
  Biochemical function     protein binding     5 terms  

 

 
PLoS One 4:e6290 (2009)
PubMed id: 19621084  
 
 
Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.
S.K.Palaninathan, N.N.Mohamedmohaideen, E.Orlandini, G.Ortore, S.Nencetti, A.Lapucci, A.Rossello, J.S.Freundlich, J.C.Sacchettini.
 
  ABSTRACT  
 
Transthyretin (TTR) is one of thirty non-homologous proteins whose misfolding, dissociation, aggregation, and deposition is linked to human amyloid diseases. Previous studies have identified that TTR amyloidogenesis can be inhibited through stabilization of the native tetramer state by small molecule binding to the thyroid hormone sites of TTR. We have evaluated a new series of beta-aminoxypropionic acids (compounds 5-21), with a single aromatic moiety (aryl or fluorenyl) linked through a flexible oxime tether to a carboxylic acid. These compounds are structurally distinct from the native ligand thyroxine and typical halogenated biaryl NSAID-like inhibitors to avoid off-target hormonal or anti-inflammatory activity. Based on an in vitro fibril formation assay, five of these compounds showed significant inhibition of TTR amyloidogenesis, with two fluorenyl compounds displaying inhibitor efficacy comparable to the well-known TTR inhibitor diflunisal. Fluorenyl 15 is the most potent compound in this series and importantly does not show off-target anti-inflammatory activity. Crystal structures of the TTR:inhibitor complexes, in agreement with molecular docking studies, revealed that the aromatic moiety, linked to the sp(2)-hybridized oxime carbon, specifically directed the ligand in either a forward or reverse binding mode. Compared to the aryl family members, the bulkier fluorenyl analogs achieved more extensive interactions with the binding pockets of TTR and demonstrated better inhibitory activity in the fibril formation assay. Preliminary optimization efforts are described that focused on replacement of the C-terminal acid in both the aryl and fluorenyl series (compounds 22-32). The compounds presented here constitute a new class of TTR inhibitors that may hold promise in treating amyloid diseases associated with TTR misfolding.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
20133122 S.Connelly, S.Choi, S.M.Johnson, J.W.Kelly, and I.A.Wilson (2010).
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
  Curr Opin Struct Biol, 20, 54-62.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.